|
|
News Breaks
|
December 13, 2011
|
| 05:26 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharma announces update to TH-302 pancreatic data | | Threshold Pharmaceuticals announced that Dr. Barry Selick, Threshold's CEO, is scheduled to present an update at the Oppenheimer 22nd Annual Healthcare Conference in New York City on the Company's corporate and clinical development. As part of the update, the Company will provide guidance that it now expects to report the primary analysis of the TH-302 Phase 2 pancreatic data in mid- to late February of 2012. Threshold completed enrollment of this trial as scheduled in June 2011 with the enrollment of 214 patients, but it has taken longer to reach the 144 progression free survival events that are required to trigger the primary analysis than originally anticipated. Over 90% of the 144 events planned for the primary analysis have occurred to date. :theflyonthewall.com |
|
|
News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 07:36 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharmaceuticals remains undervalued, says Cowen | | Cowen said Threshold Pharmaceuticals remains undervalued in relation the potential of it's TH-302 drug for pancreatic cancer. The firm noted positive Phasellb results and estimates the sales potential in the U.S. alone at $1.5B+. Shares are Outperform rated. :theflyonthewall.com |
|
|
|
|
|
